Equities

Bioxyne Ltd

Bioxyne Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Bioxyne Ltd had net income fall 586.87% from a loss of 1.94m to a larger loss of 13.33m despite a 80.91% increase in revenues from 5.15m to 9.33m.
Gross margin36.44%
Net profit margin-139.14%
Operating margin-142.72%
Return on assets-106.39%
Return on equity-136.57%
Return on investment-134.91%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Bioxyne Ltd fell by 2.82m. Cash Flow from Financing totalled 1.21m or 12.98% of revenues. In addition the company used 3.56m for operations while cash used for investing totalled 492.66k.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.0018
Tangible book value per share0.0016
More ▼

Balance sheet in AUDView more

Bioxyne Ltd has a Debt to Total Capital ratio of 5.26%.
Current ratio1.92
Quick ratio1.18
Total debt/total equity0.0508
Total debt/total capital0.0526
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.